| Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15 Y Chen, C Sun, E Landoni, L Metelitsa, G Dotti, B Savoldo Clinical cancer research 25 (9), 2915-2924, 2019 | 157 | 2019 |
| Enhancing chimeric antigen receptor T-cell efficacy in solid tumors G Fucà, L Reppel, E Landoni, B Savoldo, G Dotti Clinical cancer research 26 (11), 2444-2451, 2020 | 113 | 2020 |
| Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors K Hirabayashi, H Du, Y Xu, P Shou, X Zhou, G Fucá, E Landoni, C Sun, ... Nature cancer 2 (9), 904-918, 2021 | 74 | 2021 |
| NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease S Mastaglio, P Genovese, Z Magnani, E Ruggiero, E Landoni, B Camisa, ... Blood, The Journal of the American Society of Hematology 130 (5), 606-618, 2017 | 74 | 2017 |
| GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision K Wang, Y Chen, S Ahn, M Zheng, E Landoni, G Dotti, B Savoldo, Z Han Nature cancer 1 (10), 990-997, 2020 | 68 | 2020 |
| Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes CC Smith, S Chai, AR Washington, SJ Lee, E Landoni, K Field, J Garness, ... Cancer immunology research 7 (10), 1591-1604, 2019 | 53 | 2019 |
| In vitro elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or … S Caratelli, R Arriga, T Sconocchia, A Ottaviani, G Lanzilli, D Pastore, ... International journal of cancer 146 (1), 236-247, 2020 | 36 | 2020 |
| Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling E Landoni, G Fucá, J Wang, VR Chirasani, Z Yao, E Dukhovlinova, ... Cancer immunology research 9 (4), 441-453, 2021 | 34 | 2021 |
| CSPG4-specific CAR. CIK lymphocytes as a novel therapy for the treatment of multiple soft-tissue sarcoma histotypes V Leuci, C Donini, G Grignani, R Rotolo, G Mesiano, E Fiorino, ... Clinical Cancer Research 26 (23), 6321-6334, 2020 | 30 | 2020 |
| Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells JT Huckaby, E Landoni, TM Jacobs, B Savoldo, G Dotti, SK Lai Journal for immunotherapy of cancer 9 (9), 2021 | 29 | 2021 |
| Treating hematological malignancies with cell therapy: where are we now? E Landoni, B Savoldo Expert opinion on biological therapy 18 (1), 65-75, 2018 | 25 | 2018 |
| A high-avidity T-cell receptor redirects natural killer T-cell specificity and outcompetes the endogenous invariant T-cell receptor E Landoni, CC Smith, G Fucá, Y Chen, C Sun, BG Vincent, LS Metelitsa, ... Cancer immunology research 8 (1), 57-69, 2020 | 11 | 2020 |
| NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD S Mastaglio, P Genovese, Z Magnani, E Ruggiero, E Landoni, B Camisa Blood 130 (5), 606-18, 2017 | 11 | 2017 |
| ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK. CAR-T cells E Bergaggio, WT Tai, A Aroldi, C Mecca, E Landoni, M Nüesch, I Mota, ... Cancer cell 41 (12), 2100-2116. e10, 2023 | 6 | 2023 |
| Modified cells for immunotherapy G Dotti, E Landoni, A Shamshiev, T Kretzschmar, M Droste, D Phillips US Patent App. 16/079,202, 2019 | 2 | 2019 |
| IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity E Landoni, MG Woodcock, G Barragan, G Casirati, V Cinella, S Stucchi, ... Nature Communications 15 (1), 89, 2024 | 1 | 2024 |
| CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma L Giraudo, G Cattaneo, L Gammaitoni, I Iaia, C Donini, A Massa, ... Journal of Experimental & Clinical Cancer Research 42 (1), 310, 2023 | 1 | 2023 |
| Utilizing induced neural stem cell‐based delivery of a cytokine cocktail to enhance chimeric antigen receptor‐modified T‐cell therapy for brain cancer AS Woodell, E Landoni, A Valdivia, A Buckley, EA Ogunnaike, G Dotti, ... Bioengineering & Translational Medicine 8 (6), e10538, 2023 | 1 | 2023 |
| GD2-redirected T cells encapsulated in hydrogel control retinoblastoma and protect mouse vision K Wang, Y Chen, S Ahn, M Zheng, G Dotti, B Savoldo, Z Han Molecular therapy. Cell Press, Cambridge, MA, 2020 | 1 | 2020 |
| In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab S Caratelli, R Arriga, T Sconocchia, A Ottaviani, G Lanzilli, D Pastore, ... INTERNATIONAL JOURNAL OF CANCER 146 (1), 236-247, 2020 | 1 | 2020 |
